TP53 and colorectal carcinoma: Complementing these findings, it has been demonstrated that the phytopharmaceutical is able to suppress an inflammatory T-cell reaction by modulating the CRC-associated p53 pathway [76], which has a significant positive impact on the gut microbiome and thereby enhances 5-year survival of patients with CRC [77].